BR0213425A - Composições injetáveis para a liberação controlada de composto farmacologicamente ativo - Google Patents

Composições injetáveis para a liberação controlada de composto farmacologicamente ativo

Info

Publication number
BR0213425A
BR0213425A BR0213425-0A BR0213425A BR0213425A BR 0213425 A BR0213425 A BR 0213425A BR 0213425 A BR0213425 A BR 0213425A BR 0213425 A BR0213425 A BR 0213425A
Authority
BR
Brazil
Prior art keywords
active compound
pharmacologically active
present
controlled release
composition
Prior art date
Application number
BR0213425-0A
Other languages
English (en)
Other versions
BRPI0213425B8 (pt
BRPI0213425B1 (pt
Inventor
Yerramilli V S N Murthy
Robert Suva
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of BR0213425A publication Critical patent/BR0213425A/pt
Publication of BRPI0213425B1 publication Critical patent/BRPI0213425B1/pt
Publication of BRPI0213425B8 publication Critical patent/BRPI0213425B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES INJETáVEIS PARA A LIBERAçãO CONTROLADA DE COMPOSTO FARMACOLOGICAMENTE ATIVO". A presente invenção fornece composições e métodos para prolongar o tempo de liberação e reduzir a toxicidade do composto farmacologicamente ativo. Os compostos compreendem um sal do composto farmacologicamente ativo com um contra-íon lipofílico e um solvente farmaceuticamente aceitável solúvel em água, combinados juntos para formar uma composição injetável. O contra-íon lipofílico pode ser um ácido graxo C~ 8~-C~ 22~ não saturado ou saturado, e preferivelmente pode ser um ácido graxo C~ 10~-C~ 18~ não saturado ou saturado. Quando injetada em um mamífero, pelo menos uma porção da composição precipita e libera o composto ativo por um tempo prolongado. Desse modo, a composição forma um depósito de droga de liberação lenta do composto ativo no mamífero. Portanto, a presente invenção permite que alguém forneça uma administração de dose controlada do composto ativo durante um período de até 15 dias ou mesmo durante um tempo mais prolongado. Muitos compostos podem ser administrados de acordo com a presente invenção incluindo, porém não limitado à, tilmicosina, oxitetraciclina, metoprolol, fluoxetina, roxitromicina, e turbinafina.
BRPI0213425A 2001-10-19 2002-10-18 composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações BRPI0213425B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34362501P 2001-10-19 2001-10-19
PCT/US2002/033300 WO2003034988A2 (en) 2001-10-19 2002-10-18 Injectable compositions for the controlled delivery of pharmacologically active compound

Publications (3)

Publication Number Publication Date
BR0213425A true BR0213425A (pt) 2004-12-14
BRPI0213425B1 BRPI0213425B1 (pt) 2020-01-28
BRPI0213425B8 BRPI0213425B8 (pt) 2021-05-25

Family

ID=23346878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0213425A BRPI0213425B8 (pt) 2001-10-19 2002-10-18 composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações

Country Status (16)

Country Link
US (4) US6887487B2 (pt)
EP (1) EP1446103B1 (pt)
JP (1) JP4850390B2 (pt)
CN (2) CN101785861B (pt)
AU (1) AU2002335077B2 (pt)
BG (1) BG108634A (pt)
BR (1) BRPI0213425B8 (pt)
CA (1) CA2463896C (pt)
ES (1) ES2561108T3 (pt)
IL (1) IL160282A (pt)
MX (1) MXPA04003608A (pt)
NZ (1) NZ531460A (pt)
PL (1) PL211116B1 (pt)
RU (1) RU2292871C2 (pt)
WO (1) WO2003034988A2 (pt)
ZA (1) ZA200401076B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211116B1 (pl) * 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20070060604A1 (en) * 2002-03-25 2007-03-15 Council Of Scientific And Industrial Research Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US7854943B2 (en) 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
JP5144267B2 (ja) * 2004-10-28 2013-02-13 アイデックス ラボラトリーズ，インコーポレイティド 医薬活性化合物を制御して搬送するための組成物
WO2007016153A2 (en) * 2005-07-28 2007-02-08 Eli Lilly And Company Tilmicosin formulation
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
US7973022B2 (en) * 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
US20090239891A1 (en) * 2006-03-01 2009-09-24 Shukla Atul J Sustained Release Dosage Forms of Analgesic Medications
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
US20090005326A1 (en) * 2007-06-26 2009-01-01 Idexx Laboratories, Inc. Single dose roxithromycin
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
US8920843B2 (en) * 2007-11-07 2014-12-30 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
CN101496811B (zh) * 2008-12-24 2011-03-16 天津瑞普生物技术股份有限公司 一种可溶且稳定的替米考星组合物
CN101690713B (zh) * 2009-09-28 2011-12-28 普莱柯生物工程股份有限公司 一种喹诺酮注射液的制备方法
US20110177157A1 (en) * 2010-01-19 2011-07-21 Idexx Laboratories, Inc. Compositions for Controlled Delivery of Pharmaceutically Active Compounds
SG193434A1 (en) 2011-03-16 2013-10-30 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
ES2836325T3 (es) 2014-03-13 2021-06-24 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
CN108042491B (zh) * 2018-01-23 2021-02-09 山东迅达康兽药有限公司 一种替米考星纳米乳及其制备方法
CN113507922A (zh) * 2019-03-01 2021-10-15 勃林格殷格翰动物保健美国公司 可注射的氯舒隆组合物、其方法和用途
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
CN113730340A (zh) * 2021-09-17 2021-12-03 中国药科大学 一种注射用脂肪酸缓释组合物及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB674784A (en) * 1949-05-25 1952-07-02 Chimiotherapie Lab Franc Penicillin preparations for injection
GB731933A (en) * 1951-04-28 1955-06-15 Fougera And Company E Liquid preparations of therapeutically active substances for sub-cutaneous or intramuscular injection
US4259331A (en) * 1979-04-16 1981-03-31 Pfizer Inc. Oxytetracycline compositions
US4298375A (en) 1979-10-01 1981-11-03 Monsanto Company 2-Substituted-5-phenyl-4-thiazolecarboxylic acids and their derivatives as safening agents
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
DE3248328A1 (de) * 1982-12-28 1984-06-28 Bayer Ag, 5090 Leverkusen Schwerloesliche salze von aminoglykosiden sowie diese enthaltende formulierungen mit verzoegerter wirkstoff-freigabe
GB8725427D0 (en) * 1987-10-30 1987-12-02 Lilly Industries Ltd Somatotropin formulations
JPH027314A (ja) 1988-06-27 1990-01-11 Asahi Denso Kk スイッチ
JPH02115118A (ja) * 1988-10-24 1990-04-27 Wakunaga Pharmaceut Co Ltd 注射剤
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US5658956A (en) 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SE9202128D0 (sv) * 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
NZ250465A (en) * 1992-12-21 1995-10-26 Lilly Co Eli Bactericidal composition; contains macrolide antibiotic, use for treating aquatic species
US6110905A (en) 1994-07-09 2000-08-29 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
JP3277735B2 (ja) * 1994-12-07 2002-04-22 富士レビオ株式会社 ナフトエ酸誘導体の吸収促進組成物
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6310053B1 (en) 1995-07-05 2001-10-30 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US5723447A (en) 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
CA2263411A1 (en) * 1996-08-12 1998-02-19 Eyal S. Ron Composition for pharmaceutical applications
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
WO1998050045A1 (en) 1997-05-06 1998-11-12 Norbrook Laboratories Limited Improvements in or relating to long-acting antimicrobials
JPH11171794A (ja) * 1997-12-04 1999-06-29 Shoji Awazu 動脈注射製剤
CO5080775A1 (es) 1998-03-02 2001-09-25 Lilly Co Eli Tratamiento de enfermedad viral en cerdos
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US6328961B1 (en) 1998-08-20 2001-12-11 Bristol-Myers Squibb Company Tyrissamycin antibiotic
US6174540B1 (en) * 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20030219461A1 (en) 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US20040033938A1 (en) 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
PL211116B1 (pl) 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US6790867B2 (en) 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds

Also Published As

Publication number Publication date
CN101785861B (zh) 2014-08-13
US7033599B2 (en) 2006-04-25
PL211116B1 (pl) 2012-04-30
IL160282A (en) 2009-11-18
US20030130211A1 (en) 2003-07-10
EP1446103A4 (en) 2011-01-12
RU2004115103A (ru) 2005-03-20
EP1446103A2 (en) 2004-08-18
ZA200401076B (en) 2005-06-29
ES2561108T3 (es) 2016-02-24
JP4850390B2 (ja) 2012-01-11
CN101785861A (zh) 2010-07-28
US20070141162A1 (en) 2007-06-21
CA2463896C (en) 2010-05-04
CN1607937A (zh) 2005-04-20
US20050075296A1 (en) 2005-04-07
WO2003034988A2 (en) 2003-05-01
PL368338A1 (en) 2005-03-21
WO2003034988A3 (en) 2003-07-31
US20050163859A1 (en) 2005-07-28
BRPI0213425B8 (pt) 2021-05-25
BRPI0213425B1 (pt) 2020-01-28
EP1446103B1 (en) 2015-12-23
US7404964B2 (en) 2008-07-29
BG108634A (en) 2005-04-30
MXPA04003608A (es) 2004-07-27
US6887487B2 (en) 2005-05-03
RU2292871C2 (ru) 2007-02-10
AU2002335077B2 (en) 2006-09-07
CA2463896A1 (en) 2003-05-01
JP2005506992A (ja) 2005-03-10
NZ531460A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
BR0213425A (pt) Composições injetáveis para a liberação controlada de composto farmacologicamente ativo
RU2203653C2 (ru) Использование r-энантиомера n-пропаргил-1-аминоиндана, его солей и композиции, содержащие их
JP2706578B2 (ja) 灌注によるショック状態の処置用医薬組成物
BRPI0512177A (pt) formulação de liberação modificada de memantina
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR033688A1 (es) Composicion parenteral reconstituible
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
EP0287341B1 (en) Rectally absorbable form of l-dopa
CA1292186C (en) Rectally absorbable form of l-dopa
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
KR910009256A (ko) 식욕감소를 위한 조성물 및 그 방법
DE69719189T2 (de) Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
BR9913575A (pt) Composições compreendendo sais de amina simpatomimética inadequadas para uso ilegal
BR0210572A (pt) Composição de liberação prolongada, processo para produzir a mesma, comosição farmacêutica, agentes e método para prevenir ou tratar doenças, ou um contraceptivo, e para prevenir a recorrência de câncer de mama após a operação para câncer de mama pré-menopausal, processo para produzir um polìmero de ácido lático - ácido glicólico, polìmero de ácido lático - ácido glicólico, uso do mesmo ou de seu sal, e, microsfera
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
KR20010075621A (ko) 에스트로겐의 에난티오머를 사용한 허혈성 손상으로부터의세포 보호 방법
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
UY26620A1 (es) 4-fluoralquil -2h- benzopiranos con efecto antiestrogénico, método para su obtención, preparados farmacéuticos que los contienen y su utilización para obtener medicamentos.
WO2004091541A3 (en) Methods for the controlled delivery of pharmacologically active compounds
Sanders et al. Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse
Black et al. Elevation and depression of hepatic tyrosine transaminase activity by depletion and repletion of norepinephrine.
AR046874A1 (es) Nuevos metodos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/00, A61K 31/65, A01N 37/18, A61P 25/00, A61P 9/00, A61P 31/00

Ipc: A61K 9/00 (2011.01), A61K 31/65 (2011.01), A01N 37

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/10/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/10/2022